Hydrea Capsules 500mg №20

pharmachologic effect

Antitumor. Inhibits DNA synthesis.

Pharmacokinetics

C_max is reached 2 hours after administration. It quickly penetrates into tissues, in the cerebrospinal fluid is 10-20%, in ascitic - 15-50% concentration in plasma. After 24 hours, the serum levels approach zero. T_1 / 2 - 3-4 hours. 80% excreted by the kidneys within 12 hours.

Indications

Chronic and acute myeloid leukemia, blast crises in chronic myeloid leukemia, melanoma, carcinoma of the breast and stomach, head and neck tumors (if resection or radiation is not possible or only partially), ovarian cancer, uterine choriocarcinoma, acute lymphoblastic leukemia in children (relapses), lung cancer. It is also used in conjunction with radiation therapy (to increase its effectiveness) in cervical cancer and brain tumors.

Dosing regimen

Inside, before eating. Treatment is usually carried out by periodic courses. At 80 mg / kg once every 3 days or daily at 20-30 mg / kg once (doses are given in terms of actual or normal body weight, and the lower of these values ​​is used). In patients with old age, it is advisable to use smaller doses. During treatment, patients should consume enough liquid.

Side effect

Reversible bone marrow hypoplasia, thrombocytopenia, nausea, vomiting, partial alopecia, and spotted skin reactions.

Contraindications

Hypersensitivity, leukopenia (less than 3000 / mm ^ 3), thrombocytopenia (less than 100000 / mm ^ 3).

Pregnancy and lactation

Contraindicated.

Overdose

Symptomatic treatment, because no specific antidote; not subject to dialysis.

Drug interaction

Increases the effect of cytarabine, weakens - 5-fluorouracil and Methotrexate. At the same time taking antidepressant, antihistamine drugs, barbiturates, sedatives, sleeping pills, drugs and alcohol increases the inhibition of the reaction rate.

Terms and conditions of storage

In the dark place at a temperature of 15-25 ° C